Intended for healthcare professionals


US advice to give anticoagulants after caesarean under scrutiny

BMJ 2019; 367 doi: (Published 31 October 2019) Cite this as: BMJ 2019;367:l6325
  1. Janice Hopkins Tanne
  1. New York, USA

Controversy has arisen in the US over possible industry influence on guidance advising anticoagulant use after caesarean sections, amid doubts about the validity of the recommendations.

In 2016, the National Partnership for Maternal Safety published seven articles in the journal Obstetrics and Gynaecology. One article recommended giving anticoagulants to almost all women who had delivered a baby by caesarean section.1

Alongside the recommendations was an editorial that called the benefits of anticoagulants “uncertain” and demanded better data to support their use.2

As hospitals began implementing the recommendations, Adam C Urato, a maternal-fetal medicine specialist in Framingham, Massachusetts, found that the National Partnership, through its Industry Forum, had ties with 16 corporations. Three—Bayer, Johnson and Johnson, and Pfizer—made or sold anticoagulants.3 The industry connections were …

View Full Text

Log in

Log in through your institution


* For online subscription